Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2025
Pharmacology, Toxicology and Pharmaceutics journal rankings 2025
68 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 68 ranked journals in 2025. The median OJR rose 0.09 on 2024 to 0.72, below the world average of 1.00; Q1 starts at OJR 1.21. The highest-scoring journal with a stable rank is Drug Delivery: its likely rank is within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences68 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #3 of 68Drug DeliveryOATaylor & Francis · United Kingdom | 2.23Q1 | 9.05 0.09 down from 2024 | 415 | 100% | $2,864 | Rising vs field, 2022–25 | |
Rank 2; likely between #1 and #17 of 68Pharmaceutical Science AdvancesOAElsevier BV | 1.90Q1 | 7.02 3.11 up from 2024 | 45 | 100% | $2,000 | ||
Rank 3; likely between #1 and #9 of 68Drug SafetyAdis, Springer Healthcare · New Zealand | 1.87Q1 | 5.74 1.54 up from 2024 | 341 | 70% | $4,990 | ||
Rank 4; likely between #2 and #8 of 68Drug Delivery and Translational ResearchSpringer Science+Business Media · United States | 1.78Q1 | 7.13 1.04 up from 2024 | 631 | 49% | $4,690 | ||
Rank 5; likely between #4 and #10 of 68Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom | 1.62Q1 | 6.27 0.14 up from 2024 | 337 | 40% | — | Falling vs field, 2022–25 | |
Rank 6; likely between #3 and #14 of 68Future Journal of Pharmaceutical SciencesOASpringer Science+Business Media · Egypt | 1.59Q1 | 5.50 1.44 up from 2024 | 360 | 100% | $0 listed | Rising vs field, 2022–25 | |
Rank 7; likely between #3 and #15 of 68International Journal of Pharmaceutics XOAElsevier BV · Netherlands | 1.56Q1 | 7.14 0.27 up from 2024 | 192 | 100% | $2,590 | ||
Rank 8; likely between #1 and #22 of 68RSC PharmaceuticsOARoyal Society of Chemistry | 1.55Q1 | 6.28no 2024 value | 93 | 100% | — | — | |
Rank 9; likely between #1 and #26 of 68Frontiers in Drug Safety and RegulationOAFrontiers Media · Switzerland | 1.53Q1 | 4.49 2.23 up from 2024 | 62 | 100% | $2,353 | ||
Rank 10; likely between #3 and #16 of 68Expert Opinion on Drug Metabolism & ToxicologyTaylor & Francis · United Kingdom | 1.52Q1 | 4.62 1.19 up from 2024 | 246 | 36% | — | ||
Rank 11; likely between #2 and #19 of 68Journal of Pharmaceutical InvestigationSpringer Science+Business Media · South Korea | 1.49Q1 | 5.13 0.84 down from 2024 | 162 | 13% | $3,890 | ||
Rank 12; likely between #7 and #13 of 68International Journal of PharmaceuticsElsevier BV · Netherlands | 1.47Q1 | 6.47 0.70 up from 2024 | 3,167 | 41% | $4,650 | ||
Rank 13; likely between #4 and #17 of 68Clinical and Translational ScienceOAWiley · United Kingdom | 1.47Q1 | 4.63 1.20 up from 2024 | 747 | 100% | $3,630 | ||
Rank 14; likely between #6 and #15 of 68European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.44Q1 | 5.45 0.55 up from 2024 | 744 | 100% | $3,070 | ||
Rank 15; likely between #10 and #18 of 68AAPS PharmSciTechSpringer Science+Business Media · United States | 1.30Q1 | 5.82 1.21 up from 2024 | 767 | 31% | $4,190 | Rising vs field, 2022–25 | |
Rank 16; likely between #11 and #18 of 68European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 1.30Q1 | 5.46 0.79 up from 2024 | 787 | 39% | $4,210 | ||
Rank 17; likely between #13 and #21 of 68Pharmaceutical ResearchSpringer Science+Business Media · United States | 1.21Q1 | 4.28 0.35 down from 2024 | 617 | 40% | $4,690 | ||
Rank 18; likely between #16 and #20 of 68Journal of Drug Delivery Science and TechnologyElsevier BV · France | 1.16Q2 | 5.36 0.13 down from 2024 | 3,094 | 21% | $3,810 | ||
Rank 19; likely between #11 and #29 of 68ADMET & DMPKOAInternational Association of Physical Chemists (IAPC) · Croatia | 1.09Q2 | 4.37 0.07 down from 2024 | 106 | 100% | — | ||
Rank 20; likely between #17 and #24 of 68Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 1.05Q2 | 3.44 0.23 down from 2024 | 440 | 54% | $3,500 | ||
Rank 21; likely between #13 and #30 of 68The Pharmacogenomics JournalSpringer Nature · United Kingdom | 1.04Q2 | 2.91 0.68 down from 2024 | 92 | 35% | $4,890 | ||
Rank 22; likely between #18 and #26 of 68Expert Opinion on Drug SafetyTaylor & Francis · United Kingdom | 0.99Q2 | 2.87 0.57 down from 2024 | 557 | 15% | — | ||
Rank 23; likely between #19 and #27 of 68Journal of Analytical ToxicologyOxford University Press · United Kingdom | 0.98Q2 | 2.91 0.10 down from 2024 | 285 | 23% | $4,823 | ||
Rank 24; likely between #11 and #43 of 68AAPS OpenOASpringer Nature · Germany | 0.93Q2 | 2.12 1.33 down from 2024 | 52 | 100% | $2,090 | ||
Rank 25; likely between #21 and #36 of 68Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.85Q2 | 3.40 0.54 up from 2024 | 190 | 100% | $1,207 | Falling vs field, 2022–25 | |
Rank 26; likely between #22 and #34 of 68Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.84Q2 | 3.44 0.06 up from 2024 | 144 | 7% | — | Falling vs field, 2022–25 | |
Rank 27; likely between #23 and #37 of 68Forensic ChemistryElsevier BV · Netherlands | 0.80Q2 | 2.90 0.41 up from 2024 | 217 | 41% | $4,530 | Falling vs field, 2022–25 | |
Rank 28; likely between #20 and #43 of 68Biopharmaceutics & Drug DispositionWiley · United Kingdom | 0.80Q2 | 2.49 0.17 up from 2024 | 75 | 42% | $3,800 | ||
Rank 29; likely between #23 and #42 of 68Drug Metabolism and PharmacokineticsElsevier BV · Japan | 0.78Q2 | 2.33 0.30 up from 2024 | 121 | 4% | $3,580 | ||
Rank 30; likely between #22 and #42 of 68Forensic ToxicologySpringer Science+Business Media · Japan | 0.77Q2 | 2.25 0.69 down from 2024 | 95 | 37% | $2,990 | ||
Rank 31; likely between #26 and #38 of 68Drug Testing and AnalysisWiley · United States | 0.76Q2 | 2.48 0.28 down from 2024 | 564 | 64% | $4,440 | ||
Rank 32; likely between #25 and #42 of 68Therapeutic DeliveryFuture Science Ltd · United Kingdom | 0.73Q2 | 3.22 1.32 up from 2024 | 168 | 90% | — | ||
Rank 33; likely between #25 and #41 of 68Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.73Q2 | 3.13 0.49 up from 2024 | 279 | 12% | — | ||
Rank 34; likely between #25 and #42 of 68European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.73Q2 | 2.41 0.13 down from 2024 | 181 | 39% | $2,690 | ||
Rank 35; likely between #28 and #40 of 68Current Drug DeliveryBentham Science Publishers · Netherlands | 0.71Q3 | 3.16 0.02 up from 2024 | 345 | 8% | — | ||
Rank 36; likely between #19 and #53 of 68Pharmacology & PharmacyOAScientific Research Publishing · United States | 0.69Q3 | 2.46 0.82 up from 2024 | 100 | 100% | — | ||
Rank 37; likely between #30 and #42 of 68Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.68Q3 | 2.76 0.07 up from 2024 | 238 | 8% | — | Falling vs field, 2022–25 | |
Rank 38; likely between #23 and #49 of 68RPS Pharmacy and Pharmacology ReportsOxford University Press | 0.67Q3 | 2.27 0.56 up from 2024 | 74 | 100% | $2,852 | ||
Rank 39; likely between #27 and #46 of 68Pharmacogenetics and GenomicsLippincott Williams & Wilkins · United Kingdom | 0.66Q3 | 1.82 0.19 up from 2024 | 93 | 22% | — | ||
Rank 40; likely between #28 and #45 of 68Current Drug MetabolismBentham Science Publishers · Netherlands | 0.66Q3 | 2.53 0.70 up from 2024 | 239 | 10% | — | ||
Rank 41; likely between #31 and #47 of 68Journal of Pharmaceutical Health Care and SciencesOABioMed Central · United Kingdom | 0.62Q3 | 1.41 0.07 up from 2024 | 168 | 100% | $2,490 | ||
Rank 42; likely between #29 and #51 of 68Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 0.60Q3 | 3.17 0.31 up from 2024 | 49 | 4% | — | ||
Rank 43; likely between #37 and #46 of 68Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom | 0.59Q3 | 2.55 0.46 up from 2024 | 288 | 13% | $3,990 | Falling vs field, 2022–25 | |
Rank 44; likely between #39 and #48 of 68Pharmaceutical NanotechnologyBentham Science Publishers · Netherlands | 0.55Q3 | 2.24 0.19 up from 2024 | 206 | 0% | — | Falling vs field, 2022–25 | |
Rank 45; likely between #27 and #57 of 68Drug Metabolism and Personalized TherapyDe Gruyter · Germany | 0.55Q3 | 1.92 0.86 up from 2024 | 99 | 11% | $2,712 | ||
Rank 46; likely between #36 and #56 of 68Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.50Q3 | 2.05 0.11 down from 2024 | 97 | 3% | — | ||
Rank 47; likely between #43 and #51 of 68PharmacogenomicsFuture Medicine · United Kingdom | 0.50Q3 | 1.58 0.35 down from 2024 | 228 | 83% | — | Falling vs field, 2022–25 | |
Rank 48; likely between #39 and #55 of 68Recent Advances in Drug Delivery and FormulationNetherlands | 0.48Q3 | 2.02 0.54 up from 2024 | 90 | 2% | — | ||
Rank 49; likely between #42 and #53 of 68Recent Patents on NanotechnologyBentham Science Publishers · Netherlands | 0.47Q3 | 1.95 0.18 up from 2024 | 130 | 8% | — | ||
Rank 50; likely between #42 and #54 of 68Turkish Journal of Pharmaceutical SciencesOAGalenos Yayinevi · Türkiye | 0.47Q3 | 1.09 0.20 down from 2024 | 132 | 100% | — |
4 Pharmacology, Toxicology and Pharmaceutics journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
Full rising list for Pharmacology, Toxicology and Pharmaceutics
- 1International Journal of Pharmacy and Pharmaceutical SciencesOAPharmaceutical Science+113% vs groupOJR 0.20 → 0.43range +69% to +169%
- 2Drug DeliveryOAPharmaceutical Science+29% vs groupOJR 1.77 → 2.23range +10% to +50%
- 3AAPS PharmSciTechPharmaceutical Science+24% vs groupOJR 1.07 → 1.30range +6.9% to +44%
- 4Future Journal of Pharmaceutical SciencesOAPharmaceutical Science+31% vs groupOJR 1.24 → 1.59range +2.0% to +68%
No-label zone, -9.1% to +10%Group median changeBar scale -65% to +182% (ratio scale)
11 Pharmacology, Toxicology and Pharmaceutics journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Drug Development and Industrial PharmacyPharmaceutical Science-29% vs groupOJR 0.96 → 0.68range -41% to -14%
- 2Asian Journal of Pharmaceutical Research and DevelopmentOAPharmaceutical Science-41% vs groupOJR 0.32 → 0.19range -60% to -11%
- 3PharmacogenomicsPharmacology-27% vs groupOJR 0.69 → 0.50range -40% to -10%
- 4XenobioticaPharmacology-25% vs groupOJR 0.57 → 0.42range -40% to -6.4%
- 5Journal of MicroencapsulationPharmaceutical Science-25% vs groupOJR 1.14 → 0.84range -40% to -5.5%
- 6Pharmaceutical NanotechnologyPharmaceutical Science-40% vs groupOJR 0.94 → 0.55range -62% to -5.4%
- 7Scientia PharmaceuticaOAPharmaceutical Science-37% vs groupOJR 1.37 → 0.85range -58% to -5.3%
- 8Forensic ChemistryToxicology-24% vs groupOJR 1.08 → 0.80range -40% to -3.9%
- 9Expert Opinion on Drug DeliveryPharmaceutical Science-18% vs groupOJR 2.01 → 1.62range -30% to -3.7%
- 10Journal of Pharmaceutical InnovationPharmaceutical Science-21% vs groupOJR 0.76 → 0.59range -37% to -2.1%
- 11Brazilian Journal of Pharmaceutical SciencesOAPharmaceutical Science-25% vs groupOJR 0.51 → 0.38range -43% to -0.8%
No-label zone, -9.1% to +10%Group median changeBar scale -64% to +175% (ratio scale)
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
10 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 68
- Window papers (baseline)
- 58,541 +3.4% from indicator year 2022
- Median OJR
- 0.7176 +7.4% from indicator year 2022
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.